Black Diamond Therapeutics Q4 net loss narrows 5.43% to USD 15.12 million

Reuters03-17

<a href="https://laohu8.com/S/BDIMF">Black Diamond</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss narrows 5.43% to USD 15.12 million

Black Diamond published a fourth-quarter and full-year 2025 earnings press release, reporting Q4 net loss of USD 15.12 million, compared with a year-earlier net loss of USD 15.99 million. For FY 2025, the company posted net income of USD 22.37 million and reported license revenue of USD 70 million. FY 2025 R&D expense fell 35% to USD 33.56 million, which the company attributed to workforce efficiencies and the outlicensing of BDTX-4933 to focus on silevertinib. FY 2025 G&A expense fell 40% to USD 16.57 million, attributed to operational and workforce efficiencies tied to a restructuring announced in October 2024. Black Diamond ended 2025 with USD 128.65 million in cash, cash equivalents and investments and said it expects this to fund operations into the second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161601PRIMZONEFULLFEED9672640) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620499861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620499861","market":"fut","top_or_hot":-1,"title":"Black Diamond Therapeutics Q4 net loss narrows 5.43% to USD 15.12 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BDIMF\">Black Diamond</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q4 net loss narrows 5.43% to USD 15.12 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BDTX\">Black Diamond</a> published a fourth-quarter and full-year 2025 earnings press release, reporting Q4 net loss of USD 15.12 million, compared with a year-earlier net loss of USD 15.99 million. For FY 2025, the company posted net income of USD 22.37 million and reported license revenue of USD 70 million. FY 2025 R&amp;D expense fell 35% to USD 33.56 million, which the company attributed to workforce efficiencies and the outlicensing of BDTX-4933 to focus on silevertinib. FY 2025 G&amp;A expense fell 40% to USD 16.57 million, attributed to operational and workforce efficiencies tied to a restructuring announced in October 2024. Black Diamond ended 2025 with USD 128.65 million in cash, cash equivalents and investments and said it expects this to fund operations into the second half of 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161601PRIMZONEFULLFEED9672640) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Black Diamond Therapeutics Q4 net loss narrows 5.43% to USD 15.12 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlack Diamond Therapeutics Q4 net loss narrows 5.43% to USD 15.12 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BDIMF\">Black Diamond</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q4 net loss narrows 5.43% to USD 15.12 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BDTX\">Black Diamond</a> published a fourth-quarter and full-year 2025 earnings press release, reporting Q4 net loss of USD 15.12 million, compared with a year-earlier net loss of USD 15.99 million. For FY 2025, the company posted net income of USD 22.37 million and reported license revenue of USD 70 million. FY 2025 R&amp;D expense fell 35% to USD 33.56 million, which the company attributed to workforce efficiencies and the outlicensing of BDTX-4933 to focus on silevertinib. FY 2025 G&amp;A expense fell 40% to USD 16.57 million, attributed to operational and workforce efficiencies tied to a restructuring announced in October 2024. Black Diamond ended 2025 with USD 128.65 million in cash, cash equivalents and investments and said it expects this to fund operations into the second half of 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161601PRIMZONEFULLFEED9672640) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDTX","symbol_name":"Black Diamond Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2Z74YD:1","article_id":"2620499861","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620499861","pubTimestamp":1773691306,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Black Diamond published a fourth-quarter and full-year 2025 earnings press release, reporting Q4 net loss of USD 15.12 million, compared with a year-earlier net loss of USD 15.99 million. For FY 2025, the company posted net income of USD 22.37 million and reported license revenue of USD 70 million. FY 2025 R&D expense fell 35% to USD 33.56 million, which the company attributed to workforce efficiencies and the outlicensing of BDTX-4933 to focus on silevertinib. FY 2025 G&A expense fell 40% to USD 16.57 million, attributed to operational and workforce efficiencies tied to a restructuring announced in October 2024. Black Diamond ended 2025 with USD 128.65 million in cash, cash equivalents and investments and said it expects this to fund operations into the second half of 2028.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDTX":"Black Diamond Therapeutics, Inc.","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4588":"碎股","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Black Diamond Therapeutics第四季度净亏损收窄5.43%至1512万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BDTX":0.9},"content_text":"Black Diamond Therapeutics Q4 net loss narrows 5.43% to USD 15.12 million\n    \n\nBlack Diamond published a fourth-quarter and full-year 2025 earnings press release, reporting Q4 net loss of USD 15.12 million, compared with a year-earlier net loss of USD 15.99 million. For FY 2025, the company posted net income of USD 22.37 million and reported license revenue of USD 70 million. FY 2025 R&D expense fell 35% to USD 33.56 million, which the company attributed to workforce efficiencies and the outlicensing of BDTX-4933 to focus on silevertinib. FY 2025 G&A expense fell 40% to USD 16.57 million, attributed to operational and workforce efficiencies tied to a restructuring announced in October 2024. Black Diamond ended 2025 with USD 128.65 million in cash, cash equivalents and investments and said it expects this to fund operations into the second half of 2028.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161601PRIMZONEFULLFEED9672640) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620499861","isCrawlerRequest":true}